Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma
This article was originally published in Scrip
Executive Summary
The UK specialty ophthalmic pharma company, Altacor Limited, has entered into a collaborative agreement with Proximagen to research and develop PRX00933 – the lead compound from Proximagen's 5HT2c programme acquired as part of the acquisition of Cambridge Biotechnology – as a treatment for glaucoma. Altacor also has the option for exclusive, global rights to develop the candidate in all ophthalmic indications.